Biotech Firm Werewolf Therapeutics Faces Nasdaq Compliance Deadline

Werewolf Therapeutics, a clinical-stage biotechnology company, is now in a race against time to address a listing standards deficiency flagged by the Nasdaq Stock Market. The exchange has issued a formal warning because the company's share price remained below the critical $1.00 threshold for an extended period, putting its listing on the Nasdaq Global Select Market at risk.

The core issue stems from the stock closing below $1.00 for 30 consecutive trading days. In response, Nasdaq has granted the firm a standard grace period. Werewolf Therapeutics has until August 3, 2026, to regain compliance. To achieve this, its shares must close at or above $1.00 for a minimum of ten consecutive business days. Failure to meet this condition could lead to a transfer of its listing to the Nasdaq Capital Market, which would provide an additional 180-day compliance period. A final delisting is considered a last resort, and the company would retain the right to appeal such a decision.

This notification, received on February 4, does not trigger an immediate removal from the exchange. The company continues to trade normally for now. The primary path forward requires a sustained uplift in the stock price.

Pipeline Progress Holds the Key to Recovery

Investor focus is now squarely on the company's operational milestones as the potential catalyst for a share price recovery. Werewolf Therapeutics is advancing a pipeline of novel cancer immunotherapies, with several key data readouts expected soon.

Should investors sell immediately? Or is it worth buying Werewolf Therapeutics?

The company's management has outlined significant updates for the first half of 2026. These include the completion of the Phase 1/1b clinical trial for its drug candidate, WTX-124. Concurrently, initial data from the Phase 1b/2 study of another candidate, WTX-330, are slated for release. Both therapeutic agents are based on the company's proprietary platform designed to stimulate targeted immune responses against tumors.

Despite these clinical advancements, the company's financial position adds another layer of complexity. Werewolf Therapeutics has explicitly stated that advancing and expanding its clinical programs will require additional capital. This combination of a looming listing requirement and the need for further financing increases the pressure on management to deliver compelling clinical data. Positive results could help restore investor confidence and provide the momentum needed to lift the share price above the $1.00 benchmark.

The coming months will be decisive. The clinical data for WTX-124 and WTX-330 will ultimately test whether the company's fundamental value proposition is strong enough to drive the necessary market re-rating.